APLM – apollomics inc. - class a ordinary shares (US:NASDAQ)

News

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com